A detailed history of Twin Tree Management, LP transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Twin Tree Management, LP holds 336,400 shares of BPMC stock, worth $38.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
336,400
Previous 169,600 98.35%
Holding current value
$38.4 Million
Previous $18.3 Million 70.16%
% of portfolio
0.06%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$84.1 - $120.5 $1.01 Million - $1.44 Million
11,954 New
11,954 $1.11 Million
Q1 2024

May 09, 2024

BUY
$73.17 - $99.79 $61,755 - $84,222
844 Added 18.5%
5,406 $512,000
Q4 2023

Feb 14, 2024

BUY
$43.96 - $92.84 $200,545 - $423,536
4,562 New
4,562 $420,000
Q4 2021

Feb 10, 2022

SELL
$94.25 - $115.99 $137,605 - $169,345
-1,460 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$80.98 - $109.47 $118,230 - $159,826
1,460 New
1,460 $150,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $6.81B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Twin Tree Management, LP Portfolio

Follow Twin Tree Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Tree Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Twin Tree Management, LP with notifications on news.